Non-guideline-recommended prescribing of proton pump inhibitors: implications for the future and reducing over usage

References

• Mares-Garcia E, Palazon-Bru A, Martinez-Martin A, et al. Non-guideline-recommended prescribing of proton pump inhibitors in the general population. Curr Med Res Opin 2017:1-12
   PubMed Web of Science ®Google Scholar
• Gustafsson LL, Wettermark B, Godman B, et al. The ‘wise list’ – a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol 2011;108:224-33
   PubMed Web of Science ®Google Scholar
• Bjorkhem-Bergman L, Andersen-Karlsson E, Laing R, et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J Clin Pharmacol 2013;69(Suppl1):73-8
   Web of Science ®Google Scholar
• Donnellan C, Sweetman S, Shelley E. Health professionals’ adherence to stroke clinical guidelines: a review of the literature. Health Policy 2013;111:245-63
   PubMed Web of Science ®Google Scholar
• Taba P, Rosenthal M, Habicht J, et al. Barriers and facilitators to the implementation of clinical practice guidelines: a cross-sectional survey among physicians in Estonia. BMC Health Serv Res 2012;12:455
   PubMed Web of Science ®Google Scholar
• Fitzgerald A, Lethaby A, Cikalo M, et al. Review of Systematic Reviews Exploring the Implementation/Uptake of Guidelines. York Health Economics Consortium. Available at: https://www.nice.org.uk/guidance/ph56/evidence/evidence-review-2-431762366
   Google Scholar
• Francke AL, Smit MC, de Veer AJE, Mistiaen P. Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Informat Decis Making 2008;8:38.
   PubMed Web of Science ®Google Scholar
• Van Spall HG, Shanbhag D, Gabizon I, et al. Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocol. BMJ Open 2016;6:e009364
   PubMed Web of Science ®Google Scholar
• Barton S. Using clinical evidence. BMJ 2001;322:503-4
   PubMed Web of Science ®Google Scholar
• Bero LA, Grilli R, Grimshaw JM, et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ 1998;317:465-8
   PubMed Web of Science ®Google Scholar
• Freedberg DE, Lamousé-Smith ES, Lightdale JR, et al. Use of acid suppression medication is associated with risk for C. difficile infection in infants and children: a population-based study. Clin Infect Dis 2015;61:912-17
   PubMed Web of Science ®Google Scholar
• Godman B, Baker A, Leporowski A, et al. Initiatives to increase the prescribing of low cost generics; the case of Scotland in the international context. Med Res Arch 2017;5:1-34
   Google Scholar
• Woerkom M, Piepenbrink H, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Effect Res 2012;1:527-38
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B, van Woerkom M, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol 2014;5:106
   PubMed Web of Science ®Google Scholar
• Godman B, Shrank W, Andersen M, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoeconomics Outcomes Res 2010;10:707-22
   PubMed Web of Science ®Google Scholar
• Moon JC, Godman B, Petzold M, et al. Different initiatives across Europe to enhance losartan utilization post generics: impact and implications. Front Pharmacol 2014;5:219
   PubMed Web of Science ®Google Scholar
• Hassali MA, Wong ZY, Alrasheedy AA, et al. Perspectives of physicians practicing in low and middle income countries towards generic medicines: a narrative review. Health Policy 2014;117:297-310
   PubMed Web of Science ®Google Scholar
• Hassali MA, Alrasheedy AA, McLachlan A, et al. The experiences of implementing generic medicine policy in eight countries: a review and recommendations for a successful promotion of generic medicine use. Saudi Pharmaceut J 2014;22:491-503
   PubMed Web of Science ®Google Scholar
• Fadare JO, Adeoti AO, Desalu OO, et al. The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians. Expert Rev Pharmacoeconomics Outcomes Res 2016;16:639-50
   PubMed Web of Science ®Google Scholar
• Godman B, Bishop I, Finlayson AE, et al. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoeconomics Outcomes Res 2013;13:469-82
   PubMed Web of Science ®Google Scholar
• Nguyen TAHM, McLachlan A. Generic medicines policies in the Asia Pacific region: ways forward. WHO South-East Asia J Publ Health 2013;2:72-4
   PubMedGoogle Scholar
• Vanderstraeten G, Lejeune TM, Piessevaux H, et al. Gastrointestinal risk assessment in patients requiring non-steroidal anti-inflammatory drugs for osteoarthritis: the GIRANO study. J Rehabil Med 2016;48:705-10
   PubMed Web of Science ®Google Scholar
• Chan FK, Graham DY. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications – review and recommendations based on risk assessment. Aliment Pharmacol Therapeut 2004;19:1051-61
   PubMed Web of Science ®Google Scholar
• Patterson SM, Cadogan CA, Kerse N, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev 2014;10:Cd008165
   PubMed Web of Science ®Google Scholar
• Markovic-Pekovic V, Skrbic R, Petrovic A, et al. Polypharmacy among the elderly in the Republic of Srpska: extent and implications for the future. Expert Rev Pharmacoeconomics Outcomes Res 2016;16:609-18
   PubMed Web of Science ®Google Scholar
• Prag C, Prag M, Fredlund H. Proton pump inhibitors as a risk factor for norovirus infection. Epidemiol Infect 2017;145:1617-1623
   PubMed Web of Science ®Google Scholar
• Kvistholm Jensen A, Simonsen J, Ethelberg S. Use of proton pump inhibitors and the risk of listeriosis: a nationwide registry-based case–control study. Clin Infect Dis 2017;64:845-51
   PubMed Web of Science ®Google Scholar
• Lambert AA, Lam JO, Paik JJ, et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One 2015;10:e0128004
   PubMed Web of Science ®Google Scholar
• Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Therapeut 2011;34:1269-81
   PubMed Web of Science ®Google Scholar
• Jacob L, Hadji P, Kostev K. The use of proton pump inhibitors is positively associated with osteoporosis in postmenopausal women in Germany. Climacteric 2016;19:478-81
   PubMed Web of Science ®Google Scholar
• Andersen BN, Johansen PB, Abrahamsen B. Proton pump inhibitors and osteoporosis. Curr Opin Rheumatol 2016;28:420-5
   PubMed Web of Science ®Google Scholar
• Arora P, Gupta A, Golzy M, et al. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol 2016;17:112
   PubMed Web of Science ®Google Scholar
• Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and risk of chronic kidney disease. JAMA Intern Med 2016;176:238-46
   PubMed Web of Science ®Google Scholar
• Tleyjeh IM, Bin Abdulhak AA, Riaz M, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One 2012;7:e50836
   PubMed Web of Science ®Google Scholar
• Savarino V, Dulbecco P, de Bortoli N, et al. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med 2017;37:19-24
   PubMed Web of Science ®Google Scholar
• Garuoliene K, Godman B, Gulbinovic J, et al. Differences in utilization rates between commercial and administrative databases: implications for future health-economic and cross-national studies. Expert Rev Pharmacoeconomics Outcomes Res 2016;16:149-52
   PubMed Web of Science ®Google Scholar
• Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoeconomics Outcomes Res 2012;12:125-30
   PubMed Web of Science ®Google Scholar
• Voncina L, Strizrep T, Godman B, et al. Influence of demand-side measures to enhance renin–angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev Pharmacoeconomics Outcomes Res 2011;11:469-79
   PubMed Web of Science ®Google Scholar